CoChat

Urinary CE-MS peptide marker pattern for detection of solid tumors

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Urinary profiling datasets, previously acquired by capillary electrophoresis coupled to mass-spectrometry were investigated to identify a general urinary marker pattern for detection of solid tumors by targeting common systemic events associated with tumor-related inflammation. A total of 2,055 urinary profiles were analyzed, derived from a) a cancer group of patients (n = 969) with bladder, prostate, and pancreatic cancers, renal cell carcinoma, and cholangiocarcinoma and b) a control group of patients with benign diseases (n = 556), inflammatory diseases (n = 199) and healthy individuals (n = 331). Statistical analysis was conducted in a discovery set of 676 cancer cases and 744 controls. 193 peptides differing at statistically significant levels between cases and controls were selected and combined to a multi-dimensional marker pattern using support vector machine algorithms. Independent validation in a set of 635 patients (293 cancer cases and 342 controls) showed an AUC of 0.82. Inclusion of age as independent variable, significantly increased the AUC value to 0.85. Among the identified peptides were mucins, fibrinogen and collagen fragments. Further studies are planned to assess the pattern value to monitor patients for tumor recurrence. In this proof-of-concept study, a general tumor marker pattern was developed to detect cancer based on shared biomarkers, likely indicative of cancer-related features.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-23585-y

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of the study design and workflow of the statistical analyses for the development of the urine-based peptide biomarker pattern. The statistical analysis resulted in the discovery of 193 urinary peptides discriminating between cancer cases and non-malignant controls (p < 0.05). BH, Benjamini-Hochberg adjustment; CKD273, chronic kidney disease 273 peptide classifier; p, p-value.
Figure 1 Schematic representation of the study design and workflow of the statistical analyses for the development of the urine-based peptide biomarker pattern. The statistical analysis resulted in the discovery of 193 urinary peptides discriminating between cancer cases and non-malignant controls (p < 0.05). BH, Benjamini-Hochberg adjustment; CKD273, chronic kidney disease 273 peptide classifier; p, p-value.CC BY · PubMed Central
Figure 2 (A) ROC curve analysis for the urinary biomarker peptide pattern, consisting of 193 peptides, as performed in the independent validation cohort. The AUC, 95% CI, and p value are also provided for the classification of cancer patients. (B) The classification scores presented in Box-and-Whisker plots are displaying the level of discrimination between cancer cases and non-malignant controls and the distribution of the classification values in each population group. (A) Rank-test was performed using Kruskal-Wallis test. The average rank differences were significantly different (p < 0.05) between the controls and cancer cases. AUC, area under the curve; CI, confidence intervals, ROC, receiver operating characteristics; p, p-value.
Figure 2 (A) ROC curve analysis for the urinary biomarker peptide pattern, consisting of 193 peptides, as performed in the independent validation cohort. The AUC, 95% CI, and p value are also provided for the classification of cancer patients. (B) The classification scores presented in Box-and-Whisker plots are displaying the level of discrimination between cancer cases and non-malignant controls and the distribution of the classification values in each population group. (A) Rank-test was performed using Kruskal-Wallis test. The average rank differences were significantly different (p < 0.05) between the controls and cancer cases. AUC, area under the curve; CI, confidence intervals, ROC, receiver operating characteristics; p, p-value.CC BY · PubMed Central
Figure 3 Logistic regression analysis of ROC curve and age as independent variable. ROC, receiver operating characteristics; AUC, area under the ROC curve.
Figure 3 Logistic regression analysis of ROC curve and age as independent variable. ROC, receiver operating characteristics; AUC, area under the ROC curve.CC BY · PubMed Central
Figure 4 ROC curve analysis for the performance of combined patterns for: (A) renal cell carcinoma; (B) cholangiocarcinoma; (C) bladder cancer; (D) prostate cancer; (E) pancreatic cancer. ROC, receiver operating characteristics; AUC, area under the ROC curve.
Figure 4 ROC curve analysis for the performance of combined patterns for: (A) renal cell carcinoma; (B) cholangiocarcinoma; (C) bladder cancer; (D) prostate cancer; (E) pancreatic cancer. ROC, receiver operating characteristics; AUC, area under the ROC curve.CC BY · PubMed Central
Figure 5 Distribution of classification values for patients with autoinflammatory diseases. The following disease aetiologies were included in the specificity analysis as reference controls: hypersensitivity vasculitis (n = 58) and systemic lupus erythematosus (n = 34). HV, hypersensitivity vasculitis; SLE, systemic lupus erythematosus.
Figure 5 Distribution of classification values for patients with autoinflammatory diseases. The following disease aetiologies were included in the specificity analysis as reference controls: hypersensitivity vasculitis (n = 58) and systemic lupus erythematosus (n = 34). HV, hypersensitivity vasculitis; SLE, systemic lupus erythematosus.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 37

Metadata

Authors
Belczacka, I., Latosinska, A., Siwy, J., Metzger, J., Merseburger, A. S., Mischak, H., Vlahou, A., Frantzi, M., & Jankowski, V.
Affiliations
  • Universitätsklinikum Aachen (DE)
  • Mosaiques Diagnostics and Therapeutics (Germany) (DE)
  • University of Lübeck (DE)
  • Academy of Athens (GR)
Corresponding author
Jankowski, Vera
Venue
Scientific Reports
Published
2018-03-27
Volume
8
Issue
1
Pages
5227-5227
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2794475216
Cited by
37
References
38
Citations by year
2026: 3 · 2025: 2 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 8
FWCI
2.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • RWTH Publications (RWTH Aachen)
Funders
European Commission (622934)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Advanced Chemical Sensor Technologies
Keywords
capillary electrophoresis-mass spectrometry, tumor markers, bladder cancer, prostate cancer, pancreatic cancer, renal cell carcinoma, cholangiocarcinoma, mucin, fibrinogen fragments, collagen fragments, support vector machine classification, tumor recurrence monitoring
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Humans, Inflammation, Kidney Neoplasms, Male, Middle Aged, Neoplasm Invasiveness, Pancreatic Neoplasms, Peptides, Prostatic Neoplasms, Mass Spectrometry, Biomarkers, Tumor, Cholangiocarcinoma, Electrophoresis, Capillary, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Urinary CE-MS peptide marker pattern for detection of solid tumors. https://app.cochat.ai/papers/10.1038/s41598-018-23585-y
The paper
Belczacka, I., Latosinska, A., Siwy, J., Metzger, J., Merseburger, A. S., Mischak, H., Vlahou, A., Frantzi, M., & Jankowski, V. (2018). Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports. https://doi.org/10.1038/s41598-018-23585-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.